In a filing, BridgeBio Pharma Inc revealed its Director MCCORMICK FRANK unloaded Company’s shares for reported $4.42 million on Jun 24 ’25. In the deal valued at $44.23 per share,100,000 shares were sold. As a result of this transaction, MCCORMICK FRANK now holds 879,979 shares worth roughly $39.48 million.
Then, DENIS VON KAEPPLER IRA ROLLOVE bought 1,891 shares, generating $83,261 in total proceeds.
Before that, HANNAH VALANTINE & DENIS VON K bought 1,542 shares. BridgeBio Pharma Inc shares valued at $67,863 were divested by the spouse of bod / bod is joint o at a price of $44.01 per share.
Wolfe Research initiated its BridgeBio Pharma Inc [BBIO] rating to an Outperform in a research note published on June 17, 2025; the price target was $49. A number of analysts have revised their coverage, including Redburn Atlantic’s analysts, who began to cover the stock in late March with a ‘”a Buy”‘ rating. Scotiabank began covering BBIO with “Sector outperform” recommendation on October 16, 2024. Oppenheimer started covering the stock on October 03, 2024. It rated BBIO as “a Perform”.
Price Performance Review of BBIO
On Friday, BridgeBio Pharma Inc [NASDAQ:BBIO] saw its stock fall -0.58% to $44.86. Over the last five days, the stock has gained 7.50%. BridgeBio Pharma Inc shares have risen nearly 91.87% since the year began. Nevertheless, the stocks have risen 63.48% over the past one year. While a 52-week high of $45.18 was reached on 06/27/25, a 52-week low of $21.72 was recorded on 01/02/25.
Levels Of Support And Resistance For BBIO Stock
The 24-hour chart illustrates a support level at 44.21, which if violated will result in even more drops to 43.57. On the upside, there is a resistance level at 45.49. A further resistance level may holdings at 46.13.
How much short interest is there in BridgeBio Pharma Inc?
A steep rise in short interest was recorded in BridgeBio Pharma Inc stocks on 2025-06-13, dropping by -1.28 million shares to a total of 21.12 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 22.4 million shares. There was a decline of -6.05%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on September 04, 2024 when Piper Sandler began covering the stock and recommended ‘”an Overweight”‘ rating along with a $46 price target.
